Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly recognized. Clinical outcomes have evolved over time amidst changes in the diagnostic pathway and advances in therapeutics.

Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: Nicholas Chan, Sergio Teruya, Alfonsina Mirabal, Ariel Y. Weinsaft, Jeffeny De Los Santos, Samantha Guadalupe, Massiel Jimenez, Carlos Rodriguez, Stephen Helmke, Margaret Cuomo, Dia Smiley, Mathew S. Maurer Source Type: research